Premium
P3‐098: Did patient's cognitive status correlate with functional impairment assessment?
Author(s) -
Gorczevski Iulek,
Stefani Clarisse Luisa,
Heisler Andrea,
Godinho Claudia,
Cerveira Maria Otilia,
Silva Edla Silva,
Borba Ericksen,
Jesus Alyne G.,
Chaves Márcia L.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1593
Subject(s) - activities of daily living , dementia , clinical dementia rating , cognitive impairment , functional impairment , cognition , medicine , rating scale , psychology , physical therapy , psychiatry , disease , developmental psychology
daytime sleepiness were measured using the SCOPA-SLEEP scale during the 6-week treatment period (Baseline and Days 8, 15, 29 and 42). Results: Mean baseline (pretreatment) SCOPA Part B (nighttime sleep) scores were 10.5 for the placebo and 40 mg dose groups (N 1⁄4 97 and 92, respectively). Statistically significant improvement in nighttime sleep scores were observed in the 40 mg pimavanserin group vs. placebo as early as Day 8 (-1.0 vs. no change, p 1⁄4 0.003) and continued through Day 29. At the end of treatment (Day 42), a trend toward significance remained (-1.7 40-mg vs. -1.2 placebo; p 1⁄4 0.066). The 10 mg pimavanserin group was not significantly different from placebo at any timepoint. Daytime sleepiness scores were unaffected by pimavanserin treatment indicating no sedative effects of the drug. Conclusions: Pimavanserin appears to improve nighttime sleep without negative effects on daytime sleepiness in patients with PDP. Studies of pimavanserin in Alzheimer’s psychosis, where sleep impairment is also a common comorbidity, are planned. Evaluation of sleep in these studies may be of interest.